A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2017
Price : $35 *
At a glance
- Drugs Simtuzumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms ATLAS
- Sponsors Gilead Sciences
- 31 Aug 2018 Biomarkers information updated
- 25 Feb 2016 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
- 23 Sep 2015 Planned End Date changed from 1 Jun 2019 to 1 Jan 2018 as reported by the ClinicalTrial.gov record.